Eagle Pharmaceuticals and USAMRICD Signs an Agreement for Ryanodex (dantrolene sodium)

 Eagle Pharmaceuticals and USAMRICD Signs an Agreement for Ryanodex (dantrolene sodium)

Eagle Pharmaceuticals and USAMRICD Signs an Agreement for Ryanodex (dantrolene sodium)

 Shots:

  • United States Army Medical Research Institute of Chemical Defense (USAMRICD) and Eagle collaborates for evaluating the neuroprotective effects of Ryanodex
  • Eagle will bear the research study cost and will be conducted under a Cooperative Research and Development Agreement (CRADA), allowing government laboratories to partner with private industries or academia for R&D projects
  • If approved post research study, Ryanodex will be a novel neuroprotective treatment for amelioration of neurological damage due to nerve agent exposure

Click here to read full press release/ article | Ref: Eagle Pharmaceuticals | Image: Business wire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post